{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:40:48Z","timestamp":1790617248534,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The treatment landscape for relapsed multiple myeloma (MM) has increased. In this study, we aimed to characterize 2nd (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091439) and 3rd (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091104) line regimens and compare the results between subgroups based on the year of treatment initiation (2nd line: 2003\u20132008, 2009\u20132015, 2016\u20132021; 3rd line: 2004\u20132009, 2010\u20132015, and 2016\u20132021). In both the second- and third- lines, we observed increasing use of novel agents (from 78 to 95% and from 77 to 95%, respectively) and triplet regimens (from 15 to 69% and from 21 to 71%, respectively). The most frequently used regimens in the last studied periods included lenalidomide-dexamethasone (RD; 14%), carfilzomib-RD (12%), and daratumumab-RD (10%) for the second-line, and daratumumab-pomalidomide-dexamethasone (11%) and daratumumab-RD (10%) for the third-line. The median time to the next treatment from second-line therapy has improved from 10.4 months (95% CI: 8.4\u201312.4) to 16.6 months (95% CI: 13.3\u201320.3;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The median overall survival from the first relapse increased from 30.9 months (95% CI: 26.8\u2013183.0) to 65.8 months (95% CI: 50.7\u201372.8;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Over the last two decades, more patients were treated with newer agents and triplets for relapsed MM. The landscape of regimens has become more diverse, and survival after the first relapse is continually improving.\n                  <\/jats:p>","DOI":"10.1038\/s41408-022-00757-8","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:55:36Z","timestamp":1670295336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Second- and third-line treatment strategies in multiple myeloma: a referral-center experience"],"prefix":"10.1038","volume":"12","author":[{"given":"Sarah","family":"Goldman-Mazur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"757_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367.","journal-title":"Am J Hematol"},{"key":"757_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11864-003-0024-9","volume":"4","author":"S Singhal","year":"2003","unstructured":"Singhal S, Mehta J. Treatment of relapsed and refractory multiple myeloma. Curr Treat Options Oncol. 2003;4:229\u201337.","journal-title":"Curr Treat Options Oncol"},{"key":"757_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/ajh.21913","volume":"86","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:57\u201365.","journal-title":"Am J Hematol"},{"key":"757_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.clml.2018.04.007","volume":"18","author":"S Jagannath","year":"2018","unstructured":"Jagannath S, Abonour R, Durie BGM, Gasparetto C, Hardin JW, Narang M, et al. Heterogeneity of second-line treatment for patients with multiple myeloma in the connect MM registry (2010-2016). Clin Lymphoma Myeloma Leuk. 2018;18:480\u20135.e3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"757_CR5","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127:2955\u201362.","journal-title":"Blood"},{"key":"757_CR6","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"757_CR7","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122\u20138.","journal-title":"Leukemia"},{"key":"757_CR8","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","volume":"121","author":"X Leleu","year":"2013","unstructured":"Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du My\u00e9lome 2009-02. Blood. 2013;121:1968\u201375.","journal-title":"Blood"},{"key":"757_CR9","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014;123:1826\u201332.","journal-title":"Blood"},{"key":"757_CR10","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","volume":"119","author":"R Vij","year":"2012","unstructured":"Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma. Blood 2012;119:5661\u201370.","journal-title":"Blood"},{"key":"757_CR11","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1182\/blood-2016-05-717769","volume":"128","author":"SK Kumar","year":"2016","unstructured":"Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, et al. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood 2016;128:2415\u201322.","journal-title":"Blood"},{"key":"757_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","volume":"128","author":"SZ Usmani","year":"2016","unstructured":"Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood 2016;128:37\u201344.","journal-title":"Blood"},{"key":"757_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781\u201394.","journal-title":"Lancet Oncol"},{"key":"757_CR14","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","volume":"103","author":"A Spencer","year":"2018","unstructured":"Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica 2018;103:2079\u201387.","journal-title":"Haematologica"},{"key":"757_CR15","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1002\/cncr.31680","volume":"124","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer 2018;124:4032\u201343.","journal-title":"Cancer"},{"key":"757_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396:186\u201397.","journal-title":"Lancet"},{"key":"757_CR17","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1056\/NEJMe1609835","volume":"375","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Kyle RA. Progress in myeloma\u2014a monoclonal breakthrough. N. Engl J Med. 2016;375:1390\u20132.","journal-title":"N. Engl J Med"},{"key":"757_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94.","journal-title":"Blood Cancer J"},{"key":"757_CR19","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105\u2013e18.","journal-title":"Lancet Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00757-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T14:25:29Z","timestamp":1670595929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00757-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["757"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00757-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1995380\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prashant Kapoor: Research Funding: Takeda, Sanofi, Karyopharm, Glaxo SmithKline, Regeneron Pharmaceuticals, Ichnos Sciences, Amgen. Consultancy: Sanofi, Pharmacyclics, BeiGene, Cellectar, Karyopharm. Angela Dispenzieri: Consultancy and Research Funding: Janssen. Research Funding: Takeda, Alnylam, Pfizer. Consultancy: Oncopeptides, Sorrento Therapeutics. Morie A. Gertz, M.D: Advisory Board: Ionis Pharmaceuticals. Consultancy: Akcea Therapeutics, Alnylam Pharmaceuticals Inc, Prothena. Data Safety & Monitoring: AbbVie Inc, Celgene Corporation. Honoraria: Akcea Therapeutics, Ambry Genetics, Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc (to Institution), Sanofi Genzyme. Stock option: Aurora Biopharma. David Dingli: Consultancy: Alexion, Apellis, GSK, Sanofi, Janssen. Research Funding: Novartis. Shaji Kumar: Consultancy and Research Funding: BMS, Amgen, Roche-Genentech. Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees, and Research Funding: Abbvie, Takeda, Janssen, KITE, Astra-Zeneca. Research Funding: Tenebio, Carsgen, Merck, Novartis, Sanofi. Consultancy: Beigene, Oncopeptides, Bluebird Bio. Consultancy and Honoraria: Antengene. Membership on an entity\u2019s Board of Directors or advisory committees and Research Funding: Adaptive, Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}